Detalles de la búsqueda
1.
Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer.
Prostate
; 84(4): 342-348, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38041475
2.
Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized phase 2 trial.
Cancer
; 130(9): 1629-1641, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38161319
3.
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
Cancer
; 130(11): 2003-2013, 2024 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38297953
4.
TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type.
Oncologist
; 29(1): 8-14, 2024 Jan 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37462445
5.
A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma.
Oncologist
; 29(4): 324-331, 2024 Apr 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37950901
6.
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
Oncologist
; 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38630540
7.
Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
J Urol
; 208(4): 838-845, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36082554
8.
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.
Cancer
; 127(6): 840-849, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33216356
9.
Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
J Urol
; 205(6): 1689-1697, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33502237
10.
Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
J Urol
; 206(1): 80-87, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33683939
11.
Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies.
Ann Intern Med
; 173(5): 368-374, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32628533
12.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol
; 20(4): 581-590, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30827746
13.
Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
Prostate
; 79(1): 73-80, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30141208
14.
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Prostate
; 78(12): 889-895, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29707790
15.
Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Cancer
; 124(5): 925-933, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266178
16.
A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate Cancer.
Prostate
; 76(14): 1338-41, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27325180
17.
Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis.
Prostate
; 76(7): 691-9, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26847995
18.
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 122(3): 411-9, 2016 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26540173
19.
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Blood
; 123(10): 1461-9, 2014 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-24429336
20.
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Lancet Oncol
; 16(3): 293-300, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25681967